bemarituzumab   Click here for help

GtoPdb Ligand ID: 11278

Synonyms: FPA-144 | FPA144
Compound class: Antibody
Comment: Bemarituzumab (FPA144) is first-in-class anti-fibroblast growth factor receptor 2b (FGFR2b) chemotherapy antibody from Five Prime Therapeutics [3]. Amgen acquired Five Prime in 2021. Bemarituzumab is a humanized immunoglobulin G1 (IgG1) isotype antibody. It binds to FGFR2b and promotes ADCC via enhanced binding to FcγRIIIa. Around 30% of HER2-negative gastric cancers are FGFR2b positive and bemarituzumab is designed to target this cancer subtype that uses the FGF/FGFR pathway to promote transformation, proliferation and angiogenesis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
10681 bemarituzumab
Synonyms Click here for help
FPA-144 | FPA144
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 770
Other databases
GtoPdb PubChem SID 434321713
Search PubMed clinical trials bemarituzumab
Search PubMed titles bemarituzumab
Search PubMed titles/abstracts bemarituzumab